1. Structure and function of *α*7 nAChRs in the brain {#s0005}
=====================================================

Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that are activated by the neurotransmitter acetylcholine (ACh) for signaling, and they also respond to drugs including the nicotinic receptor agonist nicotine. The nAChRs can be classified into 5 muscle nAChR subtypes (*α*1, *β*1, *γ*/*ε*, *δ*) and 12 neuronal nAChR subtypes (*α*2--10, *β*2--4)[@bib1], [@bib2]. Among the neuronal nAChR subtypes, the *α*7 nAChR (also known as *α*7 receptor) that was first isolated and evaluated in 1990s from avian and rodents are homomeric pentamers widely distributed in the central nervous system (CNS) and periphery organs such as spleen and lymph nodes[@bib3], [@bib4], [@bib5], [@bib6], [@bib7]. The five identical *α*7 nAChR subunits are symmetrically organized around the central pore, and each subunit consists of a large amino-terminal extracellular domain (ECD), four transmembrane domains (TMD, TM1--TM4) and a cytoplasmic domain[@bib8]. In each homomeric *α*7 nAChR, there are five ACh binding sites within the ECD, which are located at the interface of every two subunits[@bib8], [@bib9].

Compared with other subtypes of nAChRs, the *α*7 nAChR exhibits unique functional properties including: 1) fast activation and desensitization by agonists (on a millisecond scale); 2) high calcium permeability (*P*~Ca~/*P*~Na~ ≈ 10); and 3) selective inhibition by *α*-bungarotoxin (*α*-Btx) and methyllycaconitine (MLA)[@bib3], [@bib4], [@bib10], [@bib11], [@bib12]. In the brain, *α*7 nAChRs are abundantly expressed in the regions underlying cognition and memory, such as the hippocampus and frontal cortex[@bib8], [@bib13]. In neurons, the presynaptically localized *α*7 nAChRs are physiologically more important although they are widely localized in the synapses (both pre- and postsynaptically) and extrasynaptically[@bib9], [@bib14]. Presynaptic *α*7 nAChRs play a major role in facilitating glutamate release in the cerebellum, auditory cortex, hippocampus and many other brain areas[@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]. Together with *α*4*β*2 nAChRs, presynaptic *α*7 nAChRs also stimulate *γ*-aminobutyric acid (GABA) release in the hippocampus[@bib21]. Postsynaptic and extrasynaptic *α*7 nAChRs are also capable of modulating neuronal activity and neurotransmission[@bib22]. In addition, the *α*7 nAChRs are also expressed in non-neuronal cells in the brain, including astrocytes, microglia, microvascular endothelial cells, and lymphocytes, playing a role in immunity, inflammation and neuroprotection[@bib9], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28].

2. The relevance of *α*7 nAChR in CNS diseases and therapy {#s0010}
==========================================================

The function of *α*7 nAChRs is critical for cognition, sensory processing, attention, working memory, and reward. On the contrary, dysfunctional *α*7 nAChRs are associated with multiple psychiatric and neurologic diseases including schizophrenia, AD, attention deficit hyperactivity disorder (ADHD), addiction, pain and Parkinson\'s disease (PD). Thus, modulation of *α*7 nAChR function is an attractive strategy for potential therapy of CNS diseases.

Schizophrenia, with a lifetime prevalence of approximately 1%, chronically and severely afflicts patients all over the world[@bib29], [@bib30]. There are at least three distinct symptoms of schizophrenia, including positive symptoms (hallucinations, delusions, thought disorder, and paranoia), negative symptoms (anhedonia, social withdrawal, and thought poverty), and cognitive dysfunction (loss of intellectual abilities such as perception, understanding, working memory, and executive function)[@bib29]. Almost all the first and second line drugs, including but not limited to chlorpromazine, clozapine, risperidone, olanzapine, and quetiapine, markedly improve positive symptoms for many patients with schizophrenia. However, they show very limited therapeutic effect on negative symptoms and cognitive dysfunction[@bib31]. Genetic studies show that *CHRNA7*, the gene encoding *α*7 nAChR protein, and a partial duplication of *CHRNA7*, *CHRFAM7A*, are associated with inhibitory sensory gating deficit in schizophrenia patients[@bib32], [@bib33]. It has also been reported that there is diminished mRNA of *CHRNA7* and decreased *α*-Btx binding in post mortem brain tissue samples from patients with schizophrenia[@bib34], [@bib35]. It has been reported that exposure to the non-selective nAChR agonist, nicotine, shows the effect of improving or normalizing sensory deficits in schizophrenia[@bib36].

Alzheimer\'s disease (AD) is a chronic neurodegenerative disorder characterized by a slow onset of memory loss and a late development of disorientation, mood swings and behavioral problems[@bib37]. The cause for AD is still mostly unknown except for less than 10% of cases in which genetic variations have been identified[@bib38]. One of the most convincing theories is that aberrant extracellular amyloid-*β* peptide (A*β*) deposits are the fundamental cause of AD[@bib39], [@bib40]. A*β* is a peptide of 36--43 amino acids crucially involved in AD as the main component of the amyloid plaques found in the brain neurons of AD patients. A*β* exhibits relatively high binding affinity with *α*7 nAChRs, and they are co-localized in cortical regions and the hippocampus in the brains of AD patients[@bib41], [@bib42]. It is controversial as to whether A*β* and its oligomers, A*β*~1--42~, are weak agonists or antagonists, but in either role, they are capable of inhibiting endogenous ACh from activating *α*7 nAChRs by desensitization or non-competitive antagonism[@bib43], [@bib44]. The A*β*--*α*7 nAChR interaction influences neurotransmission, synaptic plasticity, learning and memory[@bib45], [@bib46], [@bib47], [@bib48], [@bib49]. Directly or indirectly, the A*β*--*α*7 nAChR interaction is an important aspect of AD[@bib50]. From 1993 to 2001, several acetylcholinesterase inhibitors (AChEI) including tacrine (approved in 1993), donepezil (1996), rivastigmine (2000) and galanthamine (2001) which non-selectively enhance nAChR function have been approved for treatment of mild to moderate AD[@bib51], [@bib52]. However, there are no AChEIs approved since then. A number of AChEIs such as eptastigmine, phenserine, huperzine A, and dimebon have failed or were discontinued in clinical trials due to adverse effects or insignificant benefits[@bib53], [@bib54], [@bib55], [@bib56].

*α*7 nAChR is also reported to be relevant to other multiple CNS disorders including cigarette addiction, PD and pain[@bib57], [@bib58], [@bib59]. The opioid antagonist naltrexone, which inhibits the activity of *α*7 nAChR, was indicated for potential application in tobacco-use cessation[@bib60]. Application of the *α*7 nAChR selective agonist PNU-282987 has been shown to decrease motivation for nicotine use in rats[@bib57], [@bib61]. In the temporal cortices of post-mortem PD patients\' brains, *α*7-expressing neurons are significantly less abundant than in the control group[@bib62]. Accumulating evidence also shows that activation of *α*7 nAChR can alleviate PD symptoms in animal models[@bib58], [@bib63], [@bib64], [@bib65]. Modulation of *α*7 nAChR function by agonists and positive allosteric modulators (PAMs) exhibits antinociceptive effects in acute and persistent pain[@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72]. Genetic silencing of *α*7 reveals phenotypes of hyperalgesia and allodynia in mice, whereas *α*7-hypersensitive mice display decreased pain sensitivity[@bib59]. Altogether, these studies indicate that *α*7 nAChR serves as a potential therapeutic target for indications such as schizophrenia, AD, ADHD, addiction, pain, PD and other related CNS disorders.

3. *α*7 nAChR modulators {#s0015}
========================

Over the past two decades, medicinal chemists and biologists have carried out extensive studies in identification and evaluation of *α*7 nAChR modulators. The major focus was in finding potent and selective compounds and bringing them into therapeutic applications. As summarized in [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}[@bib73], [@bib74], [@bib75], [@bib76], [@bib77], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90], [@bib91], [@bib92], [@bib93], [@bib94], [@bib95], [@bib96], [@bib97], [@bib98], [@bib99], [@bib100], [@bib101], [@bib102], [@bib103], [@bib104], [@bib105], [@bib106], [@bib107], [@bib108], [@bib109], [@bib110], [@bib111], [@bib112], [@bib113], [@bib114], [@bib115], [@bib116], [@bib117], [@bib118], [@bib119], [@bib120], twelve *α*7 nAChR modulators were tested in clinical trials since 2006.Figure 1Current *α*7 nAChR agonists and PAMs in clinical trials for different indications. There are 11 drug candidates, of which ten agonists and one PAM are currently being tested for treatment of schizophrenia, nine agonists for AD, three agonists for nicotinic addiction, two agonists for ADHD, and one agonist each for PD and pain.Fig. 1Table 1*α*7 nAChR agonists and PAM in clinical trials.Table 1CompoundClassificationPotency & efficacyAnimal model on CNS disordersIndicationClinical status (Sponsor)TropisetronPartial agonistBinding affinity:Mice: phencyclidine-induced cognitive deficits[@bib75].PainPhase IV (completed in 2009)![](fx2.gif)*K*~i~: 6.9 nmol/L (in r*α*7)[@bib73](University Hospital, Clermont-Ferrand)Electrophysiology activity:Rats: young and aged rats[@bib76]; naloxone-induced place aversion[@bib77].H*α*7 in oocytes: EC~50~ = 0.6 μmol/L; *E*~max~ = 25%[@bib74]Smoking cessation; schizophreniaPhase III (completed in 2011)M*α*7 in oocytes: EC~50~ = 1.3 μmol/L; *E*~max~ = 36%[@bib73](Baylor College of Medicine)GTS-21/DMXB-APartial agonistBinding affinity:Rats: normal or isoflurane-induced cognitive impairment aged rats[@bib80], [@bib81], [@bib82]; ibotenic acid-induced dementia[@bib83]; mecamylamine-caused learning impairment[@bib84]; auditory gating in isolation-reared rats[@bib85]; apomorphine/MK-801-elicited PPI deficits[@bib86], [@bib87].SchizophreniaPhase II (completed in 2015)![](fx3.gif)*K*~i~: 2000 nmol/L (in h*α*7)[@bib78]Electrophysiology activity:H*α*7 in oocytes: EC~50~ = 11.0 μmol/L; *E*~max~ = 9%[@bib79](University of Colorado)R*α*7 in oocytes: EC~50~ = 5.2 μmol/L; *E*~max~ = 32%[@bib79]AD; ADHDPhase II (completed in 2008)(CoMentis)Mice: A*β*-induced cognitive deficits[@bib45]; deficient sensory inhibition[@bib88]; aggressive behavior in mouse models[@bib89].Tobacco use disorderPhase II (not yet recruiting)Rabits: aged rabbits[@bib90], [@bib91].(University of Florida)Monkeys: normal monkeys in DMTS task[@bib78]; Ketamine-induced cognitive deficit[@bib92].ABT-126AgonistBinding affinity:Monkeys: Parkinsonian monkeys[@bib95].ADPhase II (terminated in 2014)![](fx4.gif)*K*~i~: 12--14 nmol/L (in h*α*7, r*α*7 and m*α*7)[@bib93], [@bib94](AbbVie)SchizophreniaPhase II (terminated in 2014)(AbbVie)AZD0328Partial agonistBinding affinity:Mice: NOR in normal mice[@bib96], [@bib97].ADPhase I (completed in 2008)![](fx5.gif)*K*~i~: 3.0 and 4.7 nmol/L (in h*α*7 and r*α*7)[@bib96]Electrophysiology activity:Monkeys: normal monkeys in delayed response task[@bib98].Hα7 in oocytes: EC~50~ = 338 nmol/L; *E*~max~ = 64.7%[@bib96](AstraZeneca)SchizophreniaPhase II (terminated in 2008)Rα7 in oocytes: EC~50~ = 150 nmol/L; *E*~max~ = 61.0%[@bib96](AstraZeneca)BMS-933043Partial agonistBinding affinity:Rats: MK-801-induced cognitive deficits[@bib73]; *S*(+)ketamine-induced sensory gating deficits[@bib73].SchizophreniaPhase I (completed in 2013)![](fx6.gif)*K*~i~: 8.1 and 3.3 nmol/L (in h*α*7 and r*α*7)[@bib73]Ca^2+^ flux assays:H*α*7 in HEK293 cell line: EC~50~ = 23.4 nmol/L^73^(Bristol-Myers Squibb)Electrophysiology activity:H*α*7 in oocytes: EC~50~ = 0.29 μmol/L;*E*~max~ = 24%[@bib73]R*α*7 in oocytes: EC~50~ = 0.14 μmol/L; *E*~max~ = 27%[@bib73]Mice: MK-801-induced cognitive deficits[@bib73].EVP-6124/ EnceniclinePartial agonistBinding affinity:Rats: scopolamine-induced deficit[@bib99]; delay-dependent forgetting in the NOR[@bib100]; low attentive rats[@bib101].AD; dementiaPhase III (terminated in 2017)*K*~i~: 9.98 nmol/L (in r*α*7)[@bib99]![](fx7.gif)(FORUM)Electrophysiology activity:Hα7 in oocytes: EC~50~ = 0.39 μmol/L; *E*~max~ = 42%[@bib99]Schizophrenia; impaired cognitionPhase III (completed in 2016)(FORUM)Nicotine dependence; smoking cessationPhase II (terminated in 2015)(A. Eden Evins)MEM3454/RG3487Partial agonistBinding affinity:Rats: attentional performance in normal rats[@bib103]; aged rats[@bib102]; apomorphine-induced deficits in sensorimotor gating[@bib102].ADPhase II (completed in 2007)![](fx8.gif)*K*~i~: 6 nmol/L (in r*α*7)[@bib102]Electrophysiology activity:(Memory)H*α*7 in oocytes: EC~50~ = 0.8 μmol/L; *E*~max~ = 63%[@bib102]SchizophreniaPhase II (unknown)H*α*7 in QM cell line: EC~50~ = 7.7 μmol/L; *E*~max~ = 69%[@bib102](Memory)AQW051Partial agonistBinding affinity:Rats: aged rats05[@bib105]SchizophreniaPhase II (completed in 2013)![](fx9.gif)*K*~i~: 27 nmol/L^104^Ca^2+^ flux assays:Mice: NOR in normal mice[@bib105]H*α*7: EC~50~ = 7.4 μmol/L; *E*~max~ = 73%[@bib105]Monkeys: Parkinsonian monkeys[@bib106](Novartis)Electrophysiology activity:H*α*7 in oocytes: EC~50~ = 7.5 μmol/L; *E*~max~ = 75%[@bib105]Levodopa-induced dyskinesia in PDPhase II (completed in 2013)(Novartis)ADPhase II (terminated in 2009)(Novartis)TC-5619Full agonistBinding affinity:Mice: *th*(tk^--^)/*th*(tk^--^) mice[@bib108]; apomorphine-induced PPI deficits[@bib108]; NOR in normal mice[@bib108].SchizophreniaPhase II (completed in 2013)![](fx10.gif)*K*~i~: 1 and 1.4 nmol/L (in h*α*7 and r*α*7)[@bib107], [@bib108]Electrophysiology activity:(Targacept)H*α*7 in oocytes: EC~50~ = 33 nmol/L; *E*~max~ = 100%[@bib108], [@bib109]ADPhase I (completed in 2011)R*α*7 in GH4C1 cell line: EC~50~ = 17 nmol/L; *E*~max~ = 76%[@bib107](Targacept)ADHDPhase II (completed in 2012)(Targacept)SSR-180711Partial agonistBinding affinity:Rats: MK-801/PCP-induced cognitive deficits[@bib111]; depressive disorders rates[@bib111]; neurodevelopmental latent inhibition models of schizophrenia[@bib112].ADPhase II (terminated in 2008)![](fx11.gif)*K*~i~: 14 and 22 nmol/L (in h*α*7 and r*α*7)[@bib110](Sanofi)Electrophysiology activity:H*α*7 in oocytes: EC~50~ = 4.4 μmol/L; *E*~max~ = 51%[@bib110]Mice: chronic mild stress model[@bib113]; A*β*-induced memory deficits[@bib114]; phencyclidine-induced cognitive deficits[@bib115]; forced swim and tail suspension tests[@bib116]H*α*7 in GH4C1 cell line: EC~50~ = 0.9 μmol/L; *E*~max~ = 36%[@bib110]APN1125Partial agonistElectrophysiology activity:Rats: NOR in normal rats[@bib117]SchizophreniaPhase I / Phase II (suspended in 2016)(Structure Undisclosed)H*α*7 in oocytes: EC~50~ = 1.16 μmol/L; *E*~max~ = 41%[@bib117](CoMentis)AVL-3288/XY4083/CCMIType I PAMElectrophysiology activity:Mice: DBA/2 mouse model of sensory-gating deficit[@bib118]; MK-801-induced hyperlocomotion mode eight-arm radial maze in normal mice[@bib118]; NOR in normal mice[@bib119].Schizophrenia; schizoaffective disorderPhase I (recruiting)![](fx12.gif)H*α*7 in oocytes: EC~50~ = 0.7 μmol/L; *E*~max~ = 9 folds[@bib118](New York State Psychiatric Institute; University of Colorado)Rats: 5-CSRTT in normal rats[@bib119]; ketamine-induced cognitive deficits and social withdrawal[@bib120].[^1][^2]

3.1. α7 nAChR agonists {#s0020}
----------------------

Currently, most developed *α*7 nAChR agonists are partial agonists. Unlike full agonists such as endogenous ACh, *α*7 nAChR partial agonists are orthosteric ligands that can only produce a small maximal current even at concentrations where all receptors occupied[@bib121].

Tropisetron (\[(1*R*,5*S*)-8-methyl-8-azabicyclo\[3.2.1\]octan-3-yl\] 1*H*-indole-3-carboxylate), firstly identified as 5-HT~3~ receptor antagonist (*K*~i~=5.3 nmol/L), is used clinically in preventing and treating nausea and vomiting after cancer therapy[@bib122], [@bib123]. In 2001, Macor et al.[@bib123] evaluated activity of several 5-HT~3~ receptor antagonists on *α*7 nAChRs and found that tropisetron acted as a selective *α*7 nAChR partial agonist (*K*~i~=6.9 nmol/L; EC~50~ =0.6 μmol/L; *E*~max~=25%). Researchers showed that tropisetron could attenuate or improve cognitive deficits in animal models[@bib75], [@bib76], [@bib77]. However, tropisetron has not been shown to be effective in improving cognitive deficits in clinical trials. In a phase II clinical trial of tropisetron in patients with schizophrenia, administration of tropisetron significantly improved auditory sensory gating P50 deficits and sustained visual attention, which supports the safety and efficacy of adjunctive tropisetron for treatment of cognitive deficits in schizophrenia[@bib124].

GTS-21 (3-(2,4-dimethoxybenzylidene)-anabaseine), also named DMXB-A, is a derivative of the natural product anabaseine identified as an *α*7 nAChR agonist and brought into clinical trials[@bib125]. It has been extensively characterized *in vitro* and *in vivo*. This compound acts as a partial agonist in *α*7 nAChRs and displays better potency and efficacy on rat *α*7 nAChRs (EC~50~ =5.2 μmol/L; *E*~max~=32%) than with human nAChRs (EC~50~ =11 μmol/L; *E*~max~=9%) in *Xenopus* oocytes[@bib79]. Selectivity of GTS-21 is not favorable in ion flux studies as it inhibits *α*4*β*2 nAChRs (IC~50~=17 μmol/L) and activates *α*3*β*4 nAChRs (EC~50~=21 μmol/L)[@bib78]. However, in electrophysiological recordings in *Xenopus* oocytes, 100 μmol/L GTS-21 barely evoked current from *α*4*β*2 and *α*3*β*4 nAChRs[@bib83]. Extensive *in vivo* studies were carried out to confirm the pharmacological effect of GTS-21 on cognitive deficits and sensory gating models of rodents and primates ([Table 1](#t0005){ref-type="table"}). Scientists from Abbot and the University of South Florida found that intraperitoneally injecting GTS-21 significantly enhanced the learning and memory ability of aged rats in a water maze, 17-arm radical maze, and Lashley III maze tests[@bib80], [@bib81]. When the cognition of aged rats was further impaired by isoflurane, GTS-21 still could mitigate such cognitive deficits[@bib82]. Moreover, acquisition, retention and relearning abilities in eyeblink classical conditioning are much improved in GTS-21-treated aged rabbits than in the vehicle group[@bib90], [@bib91]. Cognitive deficits or dementia in rodents and primates as induced by chemical impairment could also be attenuated or normalized by treatment with GTS-21. For instance, Chen et al.[@bib45] reported that treatment with GTS-21 (1 mg/kg) perfectly prevented A*β*~25--35~ induced depression of the *α*7 nAChR response, which further led to cognitive deficits in mice. These results indicate that GTS-21 may have substantive therapeutic value in the treatment of cognitive deficit in age-associated memory impairment, AD and schizophrenia. Furthermore, sensory gating deficits in rodents could be improved with GTS-21. This compound improved deficient sensory inhibition in DBA/2 mice, and normalized auditory gating in isolation-reared rats, and also ameliorated prepulse inhibition (PPI) deficits induced by apomorphine or MK-801[@bib85], [@bib86], [@bib87], [@bib88]. These data show that GTS-21 might have a therapeutic potential for schizophrenia. In 2014, GTS-21 was in phase II clinical studies for treatment of schizophrenia, AD and ADHD. Though GTS-21 failed in improving cognition in schizophrenia patients, high dose of GTS-21 significantly improved negative symptoms in schizophrenia[@bib126]. However, GTS-21 is not a prototypical *α*7 nAChR agonist due to its relatively higher affinity for *α*4*β*2 nAChRs (*K*~i~=20 nmol/L at human and 19 nmol/L at rat) compared with *α*7 nAChRs (*K*~i~=2000 nmol/L at human and 650 nmol/L at rat)[@bib78]. Thus, the clinical benefits of GTS-21 cannot be simply attributed to *α*7 nAChR pharmacology.

The most explored structure of *α*7 nAChR agonists to date is quinuclidine derivatives such as spirooxazolidinones and quinuclidine carbamates, amides, and ethers. The first spirooxazolidinone, AR-R17779 ((--)-spiro\[1-azabicyclo\[2.2.2\]octane-3,5ʹ-oxazolidin-2ʹ-one\]) was identified and evaluated *in vitro* and *in vivo*[@bib127], [@bib128]. However, the cross reactivity with 5-HT~3~ receptors and poor penetration of AR-R17779 into the CNS remains a great challenge for clinical development[@bib22]. AZD0328 ((29 *R*)-spiro-\[1-azabicyclo\[2.2.2\]octane-3,29(39*H*)-furo\[2,3-*b*\]pyridine\] d-tartrate) is an optimized molecule identified as *α*7 nAChR agonist by AstraZeneca from the spirooxazolidinone series compounds based on AR-R17779 through structure--activity relationship (SAR) studies[@bib96]. AZD0328 acts as a partial *α*7 nAChR agonist exhibiting an EC~50~ of 338 nmol/L and an efficacy of 65% on *Xenopus* oocytes expressing human *α*7 nAChRs[@bib96]. Compared with the maximal current elicited by serotonin (5-HT) on human 5-HT~3A~ receptors and ACh on human nAChRs, maximal activity of AZD0328 was only about 12% for human 5-HT~3A~ receptors, 4% for *α*4*β*2 nAChRs and no activity on *α*3*β*4 nAChRs[@bib96]. Studies showed that AZD0328 is very stable and has favorable pharmacokinetic (PK) properties, which suggests that this compound is acceptable for clinical trials[@bib98], [@bib129]. Through activation of *α*7 nAChRs, AZD0328 is able to enhance cortical dopamine release in rats and improve novel object recognition (NOR) in mice[@bib96], [@bib97]. AZD0328 also displays efficacy in improving working memory in a spatial delayed response task in *Rhesus macaques*[@bib98]. In 2008, AstraZeneca terminated AZD0328 for a phase II clinical trial for being "unlikely to meet the current target product profile"[@bib130].

Reported in 2016, a new spirooxazolidinone named BMS-933043 ((2 *R*)-*N*-(6-(1*H*-imidazol-1-yl)-4-pyrimidinyl)-4ʹ*H*-spiro\[4-azabicyclo\[2.2.2\]octane-2,5ʹ-\[1,3\]oxazol\]-2ʹ-amine) was identified by Bristol-Myers Squibb as a selective partial agonist for the *α*7 nAChR (*K*~i~=8.1 nmol/L at human *α*7 nAChRs)[@bib73]. Preclinical studies showed cognition enhancement and sensory gating improvement in rodents[@bib73]. This compound was advanced into a phase I clinical trial for schizophrenia in 2012.

Analogs with quinuiclidine, aromatic moieties, and functional linkers such as amides and ethers have been substantially explored. EVP-6124 (((*R*)-7-chloro-*N*-quinuclidin-3-yl)benzo\[*b*\] thiophene-2-carboxamide) is a representative quinuclidine amide analog developed by FORUM (formerly EnVivo) that acts as a potent partial agonist at *α*7 nAChR (EC~50~=0.39 μmol/L, *E*~max~=42%) and an antagonist at 5-HT~3~ receptors (IC~50~\<10 nmol/L)[@bib99]. It is also reported that EVP-6124 enhanced dopamine, acetylcholine, and glutamate efflux in the rat cortex and nucleus accumbens[@bib131], [@bib132]. *In vivo*, EVP-6124 reversed scopolamine-induced deficit and improved natural forgetting and low attention in rats[@bib99], [@bib101]. Treatment with EVP-6124 in phase I and II trials for mild-to-moderate AD was well tolerated and showed statistically significant improvements compared with placebo on cognitive and functional measures[@bib133], [@bib134]. A phase II, a double-blind, randomized, placebo-controlled, parallel-design clinical trial conducted for schizophrenia showed statistical significant cognition improvement in schizophrenia patients[@bib135]. However, the results of phase III clinical trial from 2012 to 2016 for schizophrenia did not meet the primary clinical end point as high efficacy in placebo group. Consequently, the other two Phase III trials for AD and dementia were suspended in 2017. Like EVP-6124, MEM3454 ((*R*)-3-(6-*p*-tolyl-pyridin-3-yloxy)-1-aza-bicyclo\[2.2.2\]octane)developed by Memory Pharmaceuticals also exhibited antagonism at 5-HT~3~ receptors and procognitive effects in normal and aged rodents[@bib102], [@bib103]. Similarly, MEM3454 enhanced dopamine efflux by nAChR stimulation and ACh efflux primarily mediated *via* 5-HT~3~ receptor antagonism[@bib136]. In a phase II clinical trial, MEM3454 failed to improve cognitive deficits in patients with schizophrenia, but moderate negative symptoms in patients were significantly improved[@bib137]. Through homology modeling, molecular docking, and pharmacophore elucidation techniques, Targacept designed and synthesized a series of amide quinuclidine compounds, among which TC-5619 (*N*-\[2-(pyridin-3-ylmethyl)-1-azabicyclo\[2.2.2\]oct-3-yl\]-1-benzofuran-2-carboxamide) exhibits excellent activity and selectivity on *α*7 nAChR (*K*~i~=1 nmol/L at human *α*7 nAChRs, 2800 nmol/L at human *α*4*β*2 nAChRs, IC~50~\> 10 μmol/L at human 5-HT~3~ receptors)[@bib107], [@bib108]. This compound acted as an *α*7 nAChR full agonist with an EC~50~ of 33 nmol/L in *Xenopus* oocytes expressing human *α*7 nAChRs[@bib108], [@bib109]. *In vivo* studies showed adequate properties of TC-5619, including PK profiles, rapid CNS permeability and procognitive effect in rodents[@bib108], [@bib109]. However, after two phase II clinical trials were conducted, it was confirmed that TC-5619 did not improve cognitive deficits and negative symptoms in schizophrenia[@bib138], [@bib139], [@bib140].

Recently, Novartis disclosed a quinuclidine ether *α*7 nAChR partial agonist, AQW051 ((*R*)-3-(6-*p*-tolyl-pyridin-3-yloxy)-1-aza-bicyclo\[2.2.2\]octane). *In vitro* characterization with human *α*7 nAChR expressed on *Xenopus* oocytes yielded an EC~50~ of 7.5 μmol/L and an efficacy of 75%[@bib106]. Not only did it show a favorable PK profile and procognitive effects in rodents, this compound also displayed potential in the therapy of PD by reducing l-dopa-induced dyskinesias and extending the duration of l-dopa effects in parkinsonian monkeys[@bib104], [@bib105], [@bib106]. AQW051 has been advanced in phase II clinical trials for schizophrenia, AD, and l-dopa-induced PD. It was reported in a phase II randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of AQW051 in patients with PD and levodopa-induced dyskinesia that AQW051 did not significantly reduce dyskinesia or parkinsonian severity[@bib141].

Additionally, structural diversity of *α*7 nAChR agonists is continuously expanding in the literature from the series of quinuiclidine-based moieties. ABT-126 (2-(((1*R*,3*R*,4*S*,5*S*,7*S*)-1-azaadamantan-4-yl)oxy)-5-phenyl-1,3,4-thiadiazole), developed by AbbVie (formerly Abbott), is an azaadamantane derivative that acted as an *α*7 nAChR agonist (*K*~i~=12--14 nmol/L)[@bib93]. In a phase II clinical trial in patients with mild-to-moderate AD, ABT-126 demonstrated significant improvement compared with placebo in the primary efficacy endpoint[@bib93], [@bib94]. A phase II trial of ABT-126 for treatment of cognitive impairment in schizophrenia was also conducted and revealed that this compound demonstrated a procognitive effect in nonsmoking subjects[@bib142]. However, in a phase IIb clinical trial, ABT-126 did not demonstrate a consistent effect on cognition in nonsmoking subjects with schizophrenia but a trend toward an effect on negative symptoms[@bib143].

Researchers from Sanofi described a diazabicyclononane *α*7 nAChR partial agonist named SSR180711 (4-bromophenyl (1*S*,5*S*)-1,4-diazabicyclo\[3.2.2\]nonane-4-carboxylate, *K*~i~=14 nmol/L at human *α*7 nAChRs)[@bib110]. SSR180711 displayed effects of antidepression, procognition and sensory gating improvement in multiple *in vivo* studies in rodents[@bib112], [@bib113], [@bib114], [@bib116]. However, the phase II clinical trial was terminated in 2008 for insufficient expected benefit and risk. APN1125 developed by Comentis with an undisclosed structure also acted as an *α*7 nAChR partial agonist (EC~50~=1.16 μmol/L; *E*~max~=41% at human *α*7 nAChRs)[@bib117]. It is currently suspended in a phase I/phase II clinical trial for schizophrenia for business reasons[@bib144].

Most of the clinical trials conducted with *α*7 nAChR agonists showed a paucity of effects. With limited clear reports, we can only assume the lack of sufficient selectivity over 5-HT~3~ receptors and improper designation of clinical trials might be the cause of the discontinued compounds. However, the crucial function of *α*7 nAChRs in the brain and the compelling evidence of preclinical studies still suggest that selective agonists activating *α*7 nAChRs may be an attractive therapeutic strategy for schizophrenia, AD and other CNS diseases.

3.2. α7 nAChR PAMs and ago-PAMs {#s0025}
-------------------------------

A large number of compounds modulate *α*7 nAChR function by binding to allosteric sites instead of the orthosteric site that binds agonists and antagonists. *α*7 nAChR-positive allosteric modulators (PAMs) are a category of these compounds that can potentiate *α*7 currents in the presence of an agonist such as acetylcholine. On the basis of their macroscopic effects, *α*7 nAChR PAMs have been classified and distinguished as type I and type II. Type I PAMs mainly enhance agonist-evoked peak currents without delaying desensitization and do not reactivate desensitized receptors, whereas type II PAMs can delay desensitization and reactivate desensitized receptors[@bib22]. When compared with agonists, *α*7 nAChR PAMs are more promising therapeutic tools because of their maintenance of endogenous activation characteristics, better selectivity profile, higher structural diversity and better final effects with an extra neuroprotection effect[@bib145]. *α*7 nAChR ago-PAMs can activate receptors from non-orthosteric sites while still retaining the properties of PAMs.

AVL-3288 ((*E*)-*N*-(4-chlorophenyl)-3-((4-chlorophenyl)amino)-2-(3-methylisoxazol-5-yl)acrylamide), which also named XY4083 or CCMI, is a representative type I *α*7 nAChR PAM. Screened from a small library of GABA~A~ receptor PAM analogs, researchers from University of California, Irvine identified a highly selective type I *α*7 nAChR PAM, AVL-3288[@bib118]. In rodent models, treatment with AVL-3288 in the presence or absence of agonist both corrected the sensory deficits and improved cognition[@bib118], [@bib119], [@bib120], [@bib146]. In 2017, AVL-3288 has advanced into a phase I clinical trial for schizophrenia and schizoaffective disorder, which demonstrated that a type I PAM can be safely administered to humans and that it has potential positive neurocognitive effects in CNS disorders[@bib147].

NS1738 (1-(5-chloro-2-hydroxy-phenyl)-3-(2-chloro-5-trifluoromethyl-phenyl)-urea) developed by NeuroSearch and LY2087101 (\[2-\[(4-fluorophenyl)amino\]-4-methyl-5-thiazolyl\]-3-thienylmethanone) by Eli Lilly are also type I *α*7 nAChR PAMs[@bib148], [@bib149]. NS1738 was also reported to enhance agonist potency in rescuing scopolamine-induced cognitive deficits[@bib148]. Both of NS1738 and LY2087101 have not brought into clinical trials yet.

The first selective type II PAM PNU-120596 (1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea) developed by Pfizer was shown to not only potentiate the peak *α*7 current but also delay desensitization of *α*7 nAChRs[@bib150]. Though this compound augmented the procognitive effects of an acetylcholinesterase inhibitor in rodents and non-human primates, it was not able to advance into clinical trial for its potential toxic effects resulting from excessively high calcium influx[@bib118], [@bib151]. A-867744 (4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1*H*-pyrrol-1-yl)benzenesulfonamide) is type II PAM with moderate potency and efficacy (EC~50~=1.12 μmol/L; *E*~max~=733% to ACh-evoked *α*7 current in *Xenopus* oocytes) developed by AbbVie[@bib152]. Other reported type II PAMs such as TQS (4-naphthalene-1-yl-3*a*,4,5,9*b*-tetrahydro-3*H*-cyclopenta\[*c*\]quinoline-8-sulfonic acid amide), JNJ-1930942 (2-\[\[4-fluoro-3-(trifluoromethyl)phenyl\]amino\]-4-(4-pyridinyl)-5-thiazolemethanol), and RO5126946 ((5-chloro-*N*-\[(1*S*,3*R*)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl\]-2-methoxy-benzamide) also exhibited *α*7 potentiation effects *in vitro* and precognition effects *in vivo*[@bib153], [@bib154], [@bib155].

On the basis of the conventional type II *α*7 nAChR PAM TQS, researchers from Eli Lilly identified a compound named GAT-107 or 4BP-TQS (4-(4-bromophenyl)-3*a*,4,5,9*b*-tetrahydro-3*H*-cyclopenta\[*c*\]quinoline-8-sulfonamide), which exhibited potent allosteric agonism and allosteric potentiation at *α*7 nAChRs[@bib156]. Moreover, with GAT-107 as a tool, it is reported that the direct allosteric activation site is located in the interface of *α*7 nAChR subunits[@bib157], [@bib158].

Exploiting *α*7 nAChR PAMs and ago-PAMs is still in its early stages, and clinical trials of these compounds are still in their infancy. However, with the property of modulating *α*7 nAChR activity, *α*7 nAChR PAMs and ago-PAMs represent an additional therapeutic possibility for CNS diseases.

4. Concluding remarks {#s0030}
=====================

Abundant literature has shown us the critical role of *α*7 nAChRs in cognition, learning, memory, and sensory processing in animal models. Compelling preclinical evidence has shown that *α*7 nAChR agonists and PAMs could enhance cognition and alleviate sensory gating deficiency.

Most clinical trials of *α*7 nAChR agonists are terminated or suspended. With the limited data, we are not able to assign the cause of clinical failure. However, almost all of the *α*7 nAChR agonists show cross-activity with 5-HT~3~ receptors. Thus, we assume that the lack of selectivity over 5-HT~3~ receptors might be one reason for the failure of *α*7 nAChR agonists in clinical trials. In phase II clinical trials for cognitive deficits in schizophrenia, GTS-21 and ABT-126 showed significant improvement in negative symptoms but not in ameliorating cognitive deficits. In addition, EVP-6124 failed to reach the primary clinical endpoint because of the unexpected high effect of the placebo. Therefore, improper design of clinical trials might be another reason for the failure of *α*7 nAChR agonists in clinical trials.

As for *α*7 nAChR PAMs and ago-PAMs, the cytotoxic effect of PNU-120596 indicates that a too-potent activity of type II PAM is not favorable in drug discovery. However, the reported procognition and sensory gating improvement effects in animal models demonstrates a promising future for *α*7 nAChR PAMs. Moreover, positive results of AVL-3288 in a phase I clinical trial indicates that an *α*7 nAChR PAM is a potential new therapy for cognitive deficit in schizophrenia. Pharmacological studies on *α*7 nAChR ago-PAMs have not been reported yet. However, based on the activity of GAT-107 in enhancing *α*7 nAChR function, ago-PAMs remain a positive choice in developing therapeutic solution in CNS disorders.

Taken together, *α*7 nAChR agonists and PAMs (including ago-PAMs) remain a viable therapeutic strategy for the treatment of AD, schizophrenia, and other neuropsychiatric disorders. While developing *α*7 nAChR modulators, selectivity and toxicity profiles should be further improved. And before clinical trials, scientific and well-rounded clinical plans should be designed.
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[^1]: DMTS, delayed matching-to-sample; NOR, novel object recognition; PCP, neonatal phencyclidine; 5-CSRTT, five-choice serial reaction time task.

[^2]: Indications and clinical status of *α*7 nAChR modulators above are obtained from <https://clinicaltrials.gov/>.
